Communiqués Forte Biosciences, Inc.

Actions

FBRX

US34962G2084

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 01/07/2026			Varia. 5j.	Varia. 1 janv.
21,32 ^USD	+0,33%		+14,99%	-21,82%

02/06	Forte Biosciences dépose un projet d'offre 'shelf' mixte de 500 millions de dollars	MT
11/05	Forte Biosciences, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

11/05	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules	BU
11/05	Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update	BU
09/04	Forte Biosciences Announces Pricing of $150 Million Public Offering	BU
08/04	Forte Biosciences Announces Proposed Public Offering	BU
31/03	Forte Biosciences, Inc. Announces 2025 Results and Provides Update	BU
17/03	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules	BU
04/03	Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules	BU
09/02	Forte Biosciences, Inc. to Present at Upcoming Investor Meetings	BU
22/12	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules	BU
24/11	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules	BU
17/11	Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update	AQ
14/11	Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update	BU
03/11	Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences	BU
06/10/25	Forte Biosciences Inc. Reports Inducement Grants Under Nasdaq Listing Rules	AQ
03/10/25	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules	BU
15/09/25	Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium	BU
14/08/25	Forte Biosciences, Inc. Announces Results and Provides Update	BU
25/06/25	Forte Biosciences Announces Pricing of $75 Million Public Offering	BU
24/06/25	Forte Biosciences Announces Proposed Public Offering	BU
23/06/25	Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study	BU
15/05/25	Forte Biosciences, Inc. Announces Results and Provides Update	BU
31/03/25	Forte Biosciences, Inc. Announces Results and Provides Clinical Update	BU
03/02/25	Forte Biosciences, Inc. to Present at Upcoming Investor Meetings	BU
25/11/24	Forte Biosciences to Host R&D Day December 3, 2024	BU
20/11/24	FORTE BIOSCIENCES : ANNOUNCES OVERSUBSCRIBED $53 MILLION PRIVATE PLACEMENT FROM LEADING HEALTHCARE INSTITUTIONAL INVESTORS TO ADVANCE FB102 ACROSS AUTOIMMUNE INDICATIONS Form 8 K	PU